Treatment progress of peripheral T-cell lymphoma: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 17-19,26, 2015.
Artículo
en Chino
| WPRIM
| ID: wpr-602001
ABSTRACT
Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous and aggressive non-Hodgkin's lymphoma with poor prognosis under current treatment algorithm.Reports on treatment of PTCL in the 56th American Society of Hematology (ASH) annual meeting cover comprehensive aspects,among which exploration of effective low-toxicity treatment strategies for patients with PTCL is coming into the focus of this meeting.THP-COP regimen,romidepsin,bortezomib alone or in combination with panobinostat,brentuximab vedotin and stem cell transplantation provide more attractive options for both untreated and refractory/relapsed patients with PTCL,while novel drugs including Duvelisib (IPI-145),crizotinib and antiPD-1 antibody offer new hope for patients with PTCL.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Leukemia & Lymphoma
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS